Vaccine Strategy Workshop

One of the major tools in fighting infectious diseases is development of new vaccines, and we were pleased to take part in a recent Vaccine Strategy Workshop alongside colleagues from Liverpool and Malawi Liverpool Wellcome Programme.

The two-day event on the 5th & 6th of March covered many aspects of vaccine work, from delivering new candidates and supporting transition to clinical trials, to have we ensure equity in access to vaccines. We discussed the strengths we had in key areas and also what was needed to improve strength.

The meeting will feed into a broader strategy for The Pandemic Institute, and we will be holding further workshops in the coming months to focus our efforts on our other key research areas. If you are interested in being involved in future discussions please do get in touch: [email protected]. For a list of current funding calls, see below. Please get in touch if you would like support with any of these applications.

CEPI

Innovation to Prepare for Future Epidemics and Pandemics

This funding call aims to support CEPI’s mission by advancing a broad range of vaccine innovations or pathogens with pandemic potential including Disease X.

This funding call is separated into three focus areas (Third focus area is now closed to application).

Focus Area 1: advancing innovative rapid-response vaccine platforms that can transform the response to a future Disease X.
Focus Area 2: developing new vaccine candidates against CEPI priority pathogens with epidemic or pandemic potential and viral families.

Both focus area 1 and 2 are on a rolling basis through 2026.

Seeking predictors of vaccine efficacy: identifying correlates of protection to support vaccine development

This is a joint funding call in collaboration with Wellcome.

The application process is limited to maximum 1000 word.

BARDA

IMMUNECHIP+

The IMMUNECHIP+ Program is developing MPS with fully integrated immune system components to reproduce the pathology of infectious disease and exposure to other CBRN threats. The ultimate goal of this program is to position new 3D tissue models that faithfully recapitulate components of the human body as an integral part of the medical countermeasure development process. This includes efforts in platform standardization of critical components, biosensors, characterization, scaling and control over multi-tissue systems and finally, application of manufacturing processes.

Deadline: 28/09/2028

Limit of the application: 50-60 pages

Major BAA: project value exceeding $250,000